<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5635674-848F-408A-B915-A59654BEE353"><gtr:id>F5635674-848F-408A-B915-A59654BEE353</gtr:id><gtr:name>University of Eastern Finland</gtr:name><gtr:address><gtr:line1>Yliopistokatu 7</gtr:line1><gtr:line2>Box 111</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB"><gtr:id>7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB</gtr:id><gtr:name>University of Geneva</gtr:name><gtr:address><gtr:line1>University of Geneva</gtr:line1><gtr:line2>30 Quai Ernest-Ansemet</gtr:line2><gtr:postCode>CH-1211</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0EB2ECE2-59F9-4A04-B774-3F3EFD049686"><gtr:id>0EB2ECE2-59F9-4A04-B774-3F3EFD049686</gtr:id><gtr:name>Icahn School of Medicine at Mount Sinai</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2795AB81-FD33-413D-BBE4-127D1ACE6210"><gtr:id>2795AB81-FD33-413D-BBE4-127D1ACE6210</gtr:id><gtr:name>University of Chicago</gtr:name><gtr:address><gtr:line1>University of Chicago</gtr:line1><gtr:line2>5801 S Ellis Avenue</gtr:line2><gtr:line4>Chicago</gtr:line4><gtr:line5>IL 60637</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>RDM OCDEM</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5635674-848F-408A-B915-A59654BEE353"><gtr:id>F5635674-848F-408A-B915-A59654BEE353</gtr:id><gtr:name>University of Eastern Finland</gtr:name><gtr:address><gtr:line1>Yliopistokatu 7</gtr:line1><gtr:line2>Box 111</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB"><gtr:id>7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB</gtr:id><gtr:name>University of Geneva</gtr:name><gtr:address><gtr:line1>University of Geneva</gtr:line1><gtr:line2>30 Quai Ernest-Ansemet</gtr:line2><gtr:postCode>CH-1211</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0EB2ECE2-59F9-4A04-B774-3F3EFD049686"><gtr:id>0EB2ECE2-59F9-4A04-B774-3F3EFD049686</gtr:id><gtr:name>Icahn School of Medicine at Mount Sinai</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2795AB81-FD33-413D-BBE4-127D1ACE6210"><gtr:id>2795AB81-FD33-413D-BBE4-127D1ACE6210</gtr:id><gtr:name>University of Chicago</gtr:name><gtr:address><gtr:line1>University of Chicago</gtr:line1><gtr:line2>5801 S Ellis Avenue</gtr:line2><gtr:line4>Chicago</gtr:line4><gtr:line5>IL 60637</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EB134AF9-197A-4970-8C8E-6D9132EBEB02"><gtr:id>EB134AF9-197A-4970-8C8E-6D9132EBEB02</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Ian</gtr:otherNames><gtr:surname>McCarthy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1A5EBFDC-D469-430A-8CEA-AE994BEBC338"><gtr:id>1A5EBFDC-D469-430A-8CEA-AE994BEBC338</gtr:id><gtr:firstName>Fredrik</gtr:firstName><gtr:surname>Karpe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C202AF65-1865-4D4A-8448-D1B249FD97D7"><gtr:id>C202AF65-1865-4D4A-8448-D1B249FD97D7</gtr:id><gtr:firstName>Kerrin Shannon</gtr:firstName><gtr:surname>Small</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F22C9F56-9DA2-4473-8608-001C6A5F7C89"><gtr:id>F22C9F56-9DA2-4473-8608-001C6A5F7C89</gtr:id><gtr:firstName>Roger</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Cox</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ010642%2F1"><gtr:id>1F55D8C9-FE26-4588-965E-82EA3D742D5B</gtr:id><gtr:title>KLF14, adipose dysfunction, insulin resistance and type 2 diabetes: from genetic discovery to biological mechanisms and translation.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J010642/1</gtr:grantReference><gtr:abstractText>Type 2 diabetes is a major and growing cause of illness and death across the world. However, incomplete understanding of the processes involved in the development of this condition acts as a barrier to the development of better ways for treating and preventing the disease. 

In the past few years, collaborative efforts in human genetic discovery have identified over fifty positions in the human genome where individual sequence variation is associated with risk of type 2 diabetes. In principle, each of these genetic &amp;quot;signals&amp;quot; holds important clues to the mechanisms that are responsible for the maintenance of normal metabolic health. However, in most of these regions, we have yet to define the specific genetic variants responsible for the signal, or the particular genes through which the effects on diabetes-risk are mediated. As a result, the pace of biological insights has lagged behind that of genetic discovery. A key challenge for the field is to develop strategies that enable genetic signals such as these to be mined for the biological clues they can provide. 

We recently demonstrated that one of these diabetes signals maps near a gene named KLF14, and that this effect on risk of diabetes is driven by a reduced ability of insulin-sensitive tissues, including muscle and liver, to respond to insulin. We have also shown that, in fat tissue, the same variants near KLF14 have widespread effects on the levels of expression of a wide range of genes, including KLF14 itself. These data are consistent with a model whereby KLF14 acts as a major regulator of events in fat tissue, with these alterations in the levels of KLF14 leading, through as yet unspecified mechanisms, to peripheral insulin resistance and type 2 diabetes. 

The overall aim of this research is to define the molecular, cellular and physiological mechanisms which are responsible for the relationship between KLF14 and type 2 diabetes. To do this, we will pursue a number of complementary research strategies which include studies of human genetics and physiology and cellular studies in fat cells.

More specifically, our work aims to:
(a) define the specific sequence variants that are responsible for all of these effects, and how they influence levels of KLF14 within fat cells;
(b) characterise the suite of genes that are turned on and off by KLF14, and understand the consequences of those secondary changes on the function of fat tissue; and
(c) understand how it is that these KLF14-dependent changes in fat tissue lead to changes in the ability of remote tissues (such as muscle and liver) to respond to insulin. 

We expect that, by focusing on the role of KLF14 and the ways in which it leads to an increased risk of diabetes, we will gain valuable, generic insights into the mechanisms whereby events in fat have widespread metabolic effects in other tissues. An answer to this question would help us improve our understanding of the connections between obesity and diabetes, an issue of supreme importance given that much of the increase in diabetes prevalence around the world is driven by changes in the amount, distribution and function of fat. 

The research provides an opportunity to capitalise on recent discoveries in human genetics to advance understanding of disease biology. In the application, we explain how the biological information generated by this project can be exploited in directly translational studies to define novel approaches for treating, preventing, diagnosing and monitoring type 2 diabetes.</gtr:abstractText><gtr:technicalSummary>This major objective of this proposal is to define the molecular, cellular and physiological mechanisms responsible for the association between variants upstream of KLF14 and type 2 diabetes. Our recent work has demonstrated that KLF14 is a master regulator of expression in adipose tissue, and implicate this KLF14-regulated transcriptional network in the genesis of insulin resistance in remote tissues such as muscle and liver. 

The research will seek to understand the causes and consequences of altered KLF14 expression using a variety of complementary approaches that include:
(a) human genetics: resequencing, fine-mapping and epigenomic analyses; 
(b) integrative physiology: detailed metabolic analyses and genomic studies and their relationship to genotype; and 
(c) cellular studies: cellular phenotyping and genomic studies in adipocytes following knockdown and overexpression of KLF14 and selected trans-genes.

 The work has four main aims: 
(a) To characterise the molecular, cellular and physiological consequences of altered KLF14 expression;
(b) To identify the trans-genes mediating the effect of KLF14 on insulin resistance and type 2 diabetes;
(c) To define the cellular and physiological mechanisms whereby altered KLF14 expression in adipose tissue leads to generalised insulin resistance and T2D;
(d) To characterise the mechanisms whereby common variants upstream of KLF14 influence KLF14 expression.

Our research will, by elucidating the mechanisms linking KLF14 sequence variation to diabetes predisposition, provide valuable, generic, insights into the consequences of adipocyte dysfunction on whole-body physiology. The research can be expected to define novel, causally-validated, targets that are substrates for therapeutic and biomarker development, and the application sets out some of the strategies that we plan to deploy to support those translational goals.</gtr:technicalSummary><gtr:potentialImpactText>The principal beneficiaries of the research will be:
a) academics in the fields outlined in the &amp;quot;academic beneficiaries&amp;quot; section;
b) industry and biotechnology companies, in a position to exploit the improved biological understanding we seek to provide to develop novel products and services (see below);
c) the public sector (NHS, policy-makers), in the event that the research generates translational advances that provide more cost-effective means of treating and/or preventing diabetes and other insulin-resistance related diseases (e.g. hyperlipidaemias);
d) the wider public, if those translational advances provide more acceptable, more effective strategies for the treatment and prevention of those conditions.

The academic benefits will be manifest through: 
a) the generation of new knowledge related to diabetes pathogenesis, which has the potential to contribute to amelioration of the social, economic and personal costs of the &amp;quot;epidemic&amp;quot; of global diabetes;
b) the development of research models and molecules of value for academic research;
c) bolstering of research in human integrative physiology (given concerns about declining expertise);
d) improved training of researchers in the specific areas of research activity, and in the development of cross-disciplinary expertise. 

The broader economic and social impact will be manifest through:
a) economic benefits to pharma and biotechnology companies (including &amp;quot;spin-outs&amp;quot; with potential for attracting &amp;quot;inwards&amp;quot; investment) able to exploit actionable translational opportunities with respect to the development of novel therapeutic approaches (building on targets we validate) or clinically-useful biomarkers (building on candidates we identify). Given the scale of the global problem and the inadequacy of current therapeutic and preventative options, the opportunities for wealth creation are substantial;
b) improved effectiveness of public services if the biological insights result in better ways of treating and preventing T2D and related conditions (novel treatments, better diagnostics, improved strategies for stratifying risk and response to interventions);
c) transformation of public policy if the research leads, over time, to improved public health strategies for the prevention of T2D;
d) improved health outcomes (less diabetes-related morbidity and mortality, fewer diabetes complications) if the work leads to effective clinical translation, resulting in further personal, social and economic benefits. 

It is of course important to be realistic about the timelines for effective clinical translation: too often expectations in this regard are unrealistic. In practice, the time from &amp;quot;new biology&amp;quot; to &amp;quot;novel treatment&amp;quot; involves years of biological validation, target characterisation, lead molecule optimisation, and clinical evaluation. As is well-known, substantial attrition is typical at each stage. On the positive side:
a) we have recently shown (with the validation of novel biomarkers for monogenic forms of diabetes) that it is possible to move rapidly from genetic discovery to clinical utility, at least where biomarkers are concerned;
b) the massive unmet clinical need and the scale of the global problem with respect to diabetes and insulin resistance will support investments that would not be economic for other diseases;
c) the origins of our research in genetic association data means that the benefits of modulation of the KLF14 network in man have intrinsic causal validation: they also make it possible to explore the whole body effects of such modulation (including potential &amp;quot;on-target&amp;quot; side-effects) through human genetic and physiological studies, helping thereby to minimise attrition;
d) we are well-equipped, via the Target Discovery Institute in Oxford, to initiate high-throughput screens for potential small molecule modulators of this pathway, and to do so in parallel with some of the biological validation described here, thereby expediting progress.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>605221</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Eastern Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>METSIM</gtr:description><gtr:id>E783960E-40FC-4CCA-B8EA-3D1D999ABC8B</gtr:id><gtr:impact>Collaborative research</gtr:impact><gtr:outcomeId>545ea52f8bf4f7.78685057-2</gtr:outcomeId><gtr:partnerContribution>They have contributed data from their studies</gtr:partnerContribution><gtr:piContribution>We collaborate on understanding the mechanisms underlying KLF14 effects on T2D</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, Los Angeles (UCLA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine UCLA</gtr:department><gtr:description>METSIM</gtr:description><gtr:id>2E0B95EF-3F6B-4443-A991-0C764B8AC5EC</gtr:id><gtr:impact>Collaborative research</gtr:impact><gtr:outcomeId>545ea52f8bf4f7.78685057-1</gtr:outcomeId><gtr:partnerContribution>They have contributed data from their studies</gtr:partnerContribution><gtr:piContribution>We collaborate on understanding the mechanisms underlying KLF14 effects on T2D</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Icahn School of Medicine at Mount Sinai</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Adipose tissue expression</gtr:description><gtr:id>889029A4-3CC1-4582-BF20-068FC9B3B967</gtr:id><gtr:impact>Information from their proprietary data base</gtr:impact><gtr:outcomeId>EPZu8QWa6bx-1</gtr:outcomeId><gtr:partnerContribution>Information from human and murine expression studies</gtr:partnerContribution><gtr:piContribution>Collabroation over KLF14 knockout mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Chicago</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Nobrega collaboration</gtr:description><gtr:id>BEF581AB-6DE3-4EA6-89AA-74DF9AF9C533</gtr:id><gtr:impact>Marcelo Nobrega is completing studies that will add to our response to reviewers</gtr:impact><gtr:outcomeId>58c570e3460c00.54075711-1</gtr:outcomeId><gtr:partnerContribution>KLF14 ChipSeq</gtr:partnerContribution><gtr:piContribution>This is a collaboration to furnish additional data to support revision of our main manuscript which has been reviewed at Nature.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>UPenn collaboration re KLF14</gtr:description><gtr:id>4DA53FED-A3AD-4A02-B03C-1C592725CF10</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56db0be55a9a65.18055287-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data regarding role of KLF14</gtr:partnerContribution><gtr:piContribution>Sharing of data regarding role of KLF14</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STEMBANCC</gtr:description><gtr:id>06351CC0-7FDC-4B25-8CAE-9F6B020542BC</gtr:id><gtr:impact>Nil to date</gtr:impact><gtr:outcomeId>n2hkkB1ttjr-4</gtr:outcomeId><gtr:partnerContribution>We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package</gtr:partnerContribution><gtr:piContribution>This is a new IMI collaboration (total funding 53M? from IMI and in kind) to Oxford and 25 other academic institutions.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>STEMBANCC</gtr:description><gtr:id>9BDF9947-7585-49EE-82F3-D0729858FCB2</gtr:id><gtr:impact>Nil to date</gtr:impact><gtr:outcomeId>n2hkkB1ttjr-3</gtr:outcomeId><gtr:partnerContribution>We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package</gtr:partnerContribution><gtr:piContribution>This is a new IMI collaboration (total funding 53M? from IMI and in kind) to Oxford and 25 other academic institutions.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>STEMBANCC</gtr:description><gtr:id>C5D2B170-658F-4A67-B616-31F4A131D76B</gtr:id><gtr:impact>Nil to date</gtr:impact><gtr:outcomeId>n2hkkB1ttjr-1</gtr:outcomeId><gtr:partnerContribution>We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package</gtr:partnerContribution><gtr:piContribution>This is a new IMI collaboration (total funding 53M? from IMI and in kind) to Oxford and 25 other academic institutions.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Bo Ahren collaboration</gtr:description><gtr:id>F97B0F81-37F4-4F5A-9717-4FBB414220B7</gtr:id><gtr:impact>Sharing of data on adipocyte size from adipose biopsies</gtr:impact><gtr:outcomeId>58c571887492b3.01510819-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data from adipose tissue biopsies made by Bo Ahren's group</gtr:partnerContribution><gtr:piContribution>This relates to responding to reviewer comments on our Nature submission</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Geneva</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>The MUTHER (Multiple Tissues for Human Expression Resource) Consortium</gtr:description><gtr:id>7DC0A537-6037-422B-B9E0-0D58B57457FF</gtr:id><gtr:impact>We have assembled one of the largest tissue expression banks available and are instituting detailed analysis. Two papers have already been published in high profile journals (Nica, PLoS GENETICS 2010; Small Nature genetics 2011) and further publications are in preparation as of Oct 2011.</gtr:impact><gtr:outcomeId>A6517F75523-3</gtr:outcomeId><gtr:partnerContribution>it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits.</gtr:partnerContribution><gtr:piContribution>We have contributed to sample preparation, database design and to data analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The MUTHER (Multiple Tissues for Human Expression Resource) Consortium</gtr:description><gtr:id>4F48F05D-04F6-4AF5-AF2A-D5D6493E35E4</gtr:id><gtr:impact>We have assembled one of the largest tissue expression banks available and are instituting detailed analysis. Two papers have already been published in high profile journals (Nica, PLoS GENETICS 2010; Small Nature genetics 2011) and further publications are in preparation as of Oct 2011.</gtr:impact><gtr:outcomeId>A6517F75523-1</gtr:outcomeId><gtr:partnerContribution>it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits.</gtr:partnerContribution><gtr:piContribution>We have contributed to sample preparation, database design and to data analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, Los Angeles (UCLA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine UCLA</gtr:department><gtr:description>UCLA collaboration on KLF14</gtr:description><gtr:id>637980D9-605D-44A4-8C1E-1F0FAF54261E</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>56db0b8aee6308.95001352-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data regarding role of KLF14</gtr:partnerContribution><gtr:piContribution>Sharing of data regarding role of KLF14</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The MUTHER (Multiple Tissues for Human Expression Resource) Consortium</gtr:description><gtr:id>7D610F82-D93A-4318-A6FD-FE1F73E9EF09</gtr:id><gtr:impact>We have assembled one of the largest tissue expression banks available and are instituting detailed analysis. Two papers have already been published in high profile journals (Nica, PLoS GENETICS 2010; Small Nature genetics 2011) and further publications are in preparation as of Oct 2011.</gtr:impact><gtr:outcomeId>A6517F75523-2</gtr:outcomeId><gtr:partnerContribution>it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits. it has supported methods development, and provided samples and a collaborative network for analysis of expression and methylation data relevant to multiple human traits.</gtr:partnerContribution><gtr:piContribution>We have contributed to sample preparation, database design and to data analysis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novo Nordisk</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>STEMBANCC</gtr:description><gtr:id>0DB59830-A393-4CB4-92AE-51658993F374</gtr:id><gtr:impact>Nil to date</gtr:impact><gtr:outcomeId>n2hkkB1ttjr-2</gtr:outcomeId><gtr:partnerContribution>We will provide clinical material (from patients), characterise stem cell derived tissues derived and manage the diabetes work package</gtr:partnerContribution><gtr:piContribution>This is a new IMI collaboration (total funding 53M? from IMI and in kind) to Oxford and 25 other academic institutions.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Genomics for Clinicians meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D65BDC50-1303-4DF7-872D-D578756669F7</gtr:id><gtr:impact>I gave a presentation at this 4 day workshop on the value of diabetes genetics in genomic medicine</gtr:impact><gtr:outcomeId>58c55c0feb7fa6.81957599</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leena peltonen School of Human Genetics</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>27D0D518-279F-42B1-8E9B-C524F92EE8D1</gtr:id><gtr:impact>I co-organise this meeting which is attended by 20+ PhD students each year. They present to, and interact with 20+ senior academics providing a unique environment

Feedback from participants overwhelmingly positive</gtr:impact><gtr:outcomeId>rB155LcPaxY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>East Meets West Conference Hong Kong</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>165CFE18-5116-4B0E-BFFB-D38CDAD13AFD</gtr:id><gtr:impact>Lecture, debates, discussions about diabetes genetics in East Asia and beyond</gtr:impact><gtr:outcomeId>58c55d0b5e0c16.81933708</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalised genomics</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>12AF82B6-D81C-480B-B31A-14616C2275B1</gtr:id><gtr:impact>Public debate; conference presentations

Improved understanding of the issues by the audience</gtr:impact><gtr:outcomeId>30D89C026CD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2012,2013,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific presentations and seminars</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5F1E1061-8332-40A3-907A-1BDD7990BD24</gtr:id><gtr:impact>Data from these two grants has been presented at a large number of international meetings including American Diabetes Association, American Soc Human Genetics, Genomics of Common Diseases and other meetings (approx 20 a year)

Large audiences</gtr:impact><gtr:outcomeId>j4sRXgWF8X3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012,2013,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH R01</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</gtr:fundingOrg><gtr:fundingRef>DK098032</gtr:fundingRef><gtr:id>99DD5DBE-EA19-4FEC-B665-B850C4B2B255</gtr:id><gtr:outcomeId>A2MFxoo5aSk</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>Innovative Medicines Initiative BEATDKD</gtr:description><gtr:end>2022-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>BEATDKD</gtr:fundingRef><gtr:id>21F372A6-72B1-4263-BC9C-546A4410D3FD</gtr:id><gtr:outcomeId>58c55af3987064.66652555</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000000</gtr:amountPounds><gtr:country>Denmark, Kingdom of</gtr:country><gtr:currCode>DKK</gtr:currCode><gtr:currCountryCode>Denmark</gtr:currCountryCode><gtr:currLang>da_DK</gtr:currLang><gtr:department>Novo Nordisk Foundation</gtr:department><gtr:description>NovoNordisk Funden Immunometabolism</gtr:description><gtr:end>2020-04-02</gtr:end><gtr:fundingOrg>Novo Nordisk</gtr:fundingOrg><gtr:fundingRef>TRiiC</gtr:fundingRef><gtr:id>91522240-847F-4C65-9672-40B6C81DF782</gtr:id><gtr:outcomeId>58c55b4b54cdf0.51595959</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>RFP2 call for available datasets</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Foundation for the National Institutes of Health (FNIH)</gtr:fundingOrg><gtr:id>31E9CBCA-A689-4A27-8954-9C5A1A08A194</gtr:id><gtr:outcomeId>56db0daa976240.07974815</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>138271</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant- MRC KLF14</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J0106421/1</gtr:fundingRef><gtr:id>B44B2C07-6E1E-4255-A4E1-97C9A6011BC1</gtr:id><gtr:outcomeId>cWhQzowHVEk</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute of Mental Health (NIMH)</gtr:department><gtr:description>NIH R01</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>MH101814</gtr:fundingRef><gtr:id>2C15FA49-110E-4847-A1FF-5D418B19AEC1</gtr:id><gtr:outcomeId>HBuVnPqPxJK</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>U01</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</gtr:fundingOrg><gtr:fundingRef>DK105535</gtr:fundingRef><gtr:id>7CD98E3C-30CB-4529-9E0F-ADCE2A37043A</gtr:id><gtr:outcomeId>56db0e17af7311.23177741</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Program grant</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9451DBD8-E983-4879-AC1F-2F0EE3D560E6</gtr:id><gtr:outcomeId>545e9fa9db9421.11292959</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Experimental Challenges Grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>99DA86FB-1069-40B7-BD65-E4E465D9CE72</gtr:id><gtr:outcomeId>544c3caa79d399.55945940</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>Innovative Medicines Initiative RHAPSODY</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>7EA1954F-A8BC-4620-9A57-357B6C99A930</gtr:id><gtr:outcomeId>58c55a888a4ed2.39498570</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award (WTCHG/WIMM)</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>106130/Z/14/Z</gtr:fundingRef><gtr:id>820CB605-0B57-4989-9103-7A443BD51546</gtr:id><gtr:outcomeId>56db0d06e81565.50205403</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Global KLF14 knockout mouse</gtr:description><gtr:id>1F97A22F-C258-4A82-AB01-B10AC69B6A60</gtr:id><gtr:impact>No recapitulation of the human phenotype in this mouse</gtr:impact><gtr:outcomeId>UniverhWDhB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>KLF14 knockout mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>17897547-03C7-4B9D-99AF-69BDA6EBD357</gtr:id><gtr:title>10 Years of GWAS Discovery: Biology, Function, and Translation.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/859b4c9c91debc87b0ecb1ee29833892"><gtr:id>859b4c9c91debc87b0ecb1ee29833892</gtr:id><gtr:otherNames>Visscher PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5aa6fa73705be9.72555318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C3206E4-BE31-4987-B7DC-B3A6784AA244</gtr:id><gtr:title>Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c37eb62fe3972982ee930d1edf9d20cf"><gtr:id>c37eb62fe3972982ee930d1edf9d20cf</gtr:id><gtr:otherNames>Civelek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5a7b1c1b075605.77905477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB9B1E0B-CD3C-4914-8D6C-043596FFD12D</gtr:id><gtr:title>New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d79b292e8eb56ca2326c9e5e6cf91fc"><gtr:id>0d79b292e8eb56ca2326c9e5e6cf91fc</gtr:id><gtr:otherNames>Lu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56c0ee1be4c595.13720590</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J010642/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>